Glycoprofiling analysis was able to distinguish benign ovarian neoplasms from invasive epithelial ovarian/tubule cancer with a specificity of 61.1% at 90% sensitivity, whereas the CA125 specificity for the commercial assay was only 41.3% at the same sensitivity. The gene discussed is MUC16; the disease is ovarian benign neoplasm.